Goldman Sachs Upgrades Eli Lilly (LLY) to Neutral on New "Hope Trade"
Tweet
Share
E-mailGet Alerts LLY Hot Sheet
Price: $1,180.16 -2.25%
Rating Summary:
30 Buy, 5 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
30 Buy, 5 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs upgraded Eli Lilly (NYSE: LLY) from Sell to Neutral with a price target of $54.00 (from $42.00) saying the Sola data supports optionality trade.
New solanezumab data provides a backbone for the recent "hope trade," the firm notes.
"Our skepticism was proven wrong as the data presented at ANA today demonstrates that the beta amyloid thesis is alive and well and that sola could conceivably reach the market in 3-4 years," the analyst said.
For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.
Shares of Eli Lilly closed at $50.78 yesterday.
New solanezumab data provides a backbone for the recent "hope trade," the firm notes.
"Our skepticism was proven wrong as the data presented at ANA today demonstrates that the beta amyloid thesis is alive and well and that sola could conceivably reach the market in 3-4 years," the analyst said.
For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.
Shares of Eli Lilly closed at $50.78 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- New Street Research Upgrades Micron Technology (MU) to Buy
- Citi upgrades Establishment Labs to Buy with $92 target
- Jefferies Upgrades Brightstar Lottery (BRSL) to Buy
Create E-mail Alert Related Categories
Analyst PT Change, Hot Upgrades, UpgradesRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
